A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108)

Researchers want to learn if V503 (also called the 9‐valent human papillomavirus [9vHPV]vaccine, recombinant) can induce an immune response to HPV types 6, 11, 16, 18, 31, 33,45, 52, and 58 in Chinese females who previously received the bivalent HPV (2vHPV)vaccine.The 9vHPV vaccine protects against diseases caused by 9 types of HPV (6, 11, 16, 18, 31,33, 45, 52, and 58) and the 2vHPV vaccine protects against diseases caused by 2 types ofHPV (16 and 18).The goals of the trial are to learn: ‐ If the 9vHPV vaccine can induce an immune response to HPV types 6, 11, 16, 18, 31,33, 45, 52, and 58 in participants who received the 2vHPV vaccine ‐ About the safety of the 9vHPV vaccine in prior 2vHPV vaccine recipients